DiaMedica Therapeutics, Inc. (DMAC)
8.25
+0.23
(+2.87%)
USD |
NASDAQ |
Nov 20, 16:00
8.255
0.00 (0.00%)
After-Hours: 20:00
DiaMedica Therapeutics Research and Development Expense (TTM) : 32.08M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 32.08M |
| June 30, 2026 | 29.28M |
| March 31, 2026 | 26.94M |
| December 31, 2025 | 24.61M |
| September 30, 2025 | 24.38M |
| June 30, 2025 | 22.93M |
| March 31, 2025 | 21.04M |
| December 31, 2024 | 19.06M |
| September 30, 2024 | 16.26M |
| June 30, 2024 | 14.55M |
| March 31, 2024 | 13.17M |
| December 31, 2023 | 13.11M |
| September 30, 2023 | 11.70M |
| June 30, 2023 | 10.07M |
| March 31, 2023 | 9.483M |
| December 31, 2022 | 7.839M |
| September 30, 2022 | 7.44M |
| June 30, 2022 | 8.132M |
| March 31, 2022 | 8.333M |
| December 31, 2021 | 8.765M |
| September 30, 2021 | 10.01M |
| June 30, 2021 | 9.862M |
| March 31, 2021 | 9.335M |
| December 31, 2020 | 8.31M |
| September 30, 2020 | 6.992M |
| Date | Value |
|---|---|
| June 30, 2020 | 6.429M |
| March 31, 2020 | 6.674M |
| December 31, 2019 | 7.90M |
| September 30, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | 3.781M |
| June 30, 2018 | 3.060M |
| March 31, 2018 | 3.129M |
| December 31, 2017 | 3.496M |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | 1.635M |
| June 30, 2016 | 1.038M |
| March 31, 2016 | 0.8746M |
| December 31, 2015 | 0.9576M |
| September 30, 2015 | 1.223M |
| June 30, 2015 | 1.525M |
| March 31, 2015 | 2.242M |
| December 31, 2014 | 3.644M |
| September 30, 2014 | 4.252M |
| June 30, 2014 | 4.978M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 929.60M |
| Nektar Therapeutics | 148.61M |
| Fortress Biotech, Inc. | 2.656M |
| ACADIA Pharmaceuticals, Inc. | 319.46M |
| Alnylam Pharmaceuticals, Inc. | 1.559B |